Michael Spinella

Prof. Dr. Michael Spinella

University of Illinois Champaign Urbana, Urbana, IL 61802, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RBRaya Iman Boyd
Raya Iman Boyd
SASaeed Ahmad
Saeed Ahmad
Ratnakar SinghRatnakar Singh
Ratnakar Singh
ZFZeeshan fazal
Zeeshan fazal
GPGail Prins
Gail Prins
Michael SpinellaMichael Spinella
Michael Spinella
Poly- and perfluoroalkylated substances (PFAS) are chemicals that persist and bioaccumulate in the environment and are found in nearly all human populations through several routes of exposure. Human occupational and community exposure to PFAS has been associated with several cancers, including cancers of the kidney, testis, prostate, and liver. While evidence suggests that PFAS are not directly mutagenic, many diverse mechanisms of carcinogenicity have been proposed. In this mini-review, we organize these mechanisms into three major proposed pathways of PFAS action—metabolism, endocrine disruption, and epigenetic perturbation—and discuss how these distinct but interdependent pathways may explain many of the proposed pro-carcinogenic effects of the PFAS class of environmental contaminants. Notably, each of the pathways is predicted to be highly sensitive to the dose and window of exposure which may, in part, explain the variable epidemiologic and experimental evidence linking PFAS and cancer. We highlight testicular and prostate cancer as models to validate this concept.

7 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CACostantine Albany
Costantine Albany
MHMary P. Hever-Jardine
Mary P. Hever-Jardine
KHKatherine M. von Herrmann
Katherine M. von Herrmann
CYChristina Y. Yim
Christina Y. Yim
JTJanice Tam
Janice Tam
Michael SpinellaMichael Spinella
Michael Spinella
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine

29 December 2022 in Toxics
Verified
Journal Article
Open access
PDF file
XZXing Zhang
Xing Zhang
Jodi FlawsJodi Flaws
Jodi Flaws
Michael SpinellaMichael Spinella
Michael Spinella
JIJoseph Irudayaraj
Joseph Irudayaraj
Endocrine disrupting chemicals (EDCs) are exogenous substances that alter the endocrine function of an organism, to result in adverse effects on growth and development, metabolism, and reproductive function. The kidney is one of the most important organs in the urinary system and an accumulation point. Studies have shown that EDCs can cause proteinuria, affect glomeruli and renal tubules, and even lead to diabetes and renal fibrosis in animal and human studies. In this review, we discuss renal accumulation of select EDCs such as dioxins, per- and polyfluoroalkyl substances (PFAS), bisphenol A (BPA), and phthalates, and delineate how exposures to such EDCs cause renal lesions and diseases, including cancer. The regulation of typical EDCs with specific target genes and the activation of related pathways are summarized.

30 October 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
OIOzan Imir
Ozan Imir
AKAlanna Zoe Kaminsky
Alanna Zoe Kaminsky
QZQIANYING ZUO
QIANYING ZUO
YLYu-Jeh Liu
Yu-Jeh Liu
Ratnakar SinghRatnakar Singh
Ratnakar Singh
ZMZeynep Madak-Erdogan
Zeynep Madak-Erdogan
Per- and polyfluoroalkyl substances (PFAS) are synthetic chemicals utilized in various industrial settings and include products such as flame retardants, artificial film-forming foams, cosmetics, and non-stick cookware, among others. Epidemiological studies suggest a link between increased blood PFAS levels and prostate cancer incidence, but the mechanism through which PFAS impact cancer development is unclear. To investigate the link between PFAS and prostate cancer, we evaluated the impact of metabolic alterations resulting from a high-fat diet combined with PFAS exposure on prostate tumor progression. We evaluated in vivo prostate cancer xenograft models exposed to perfluorooctane sulfonate (PFOS), a type of PFAS compound, and different diets to study the effects of PFAS on prostate cancer progression and metabolic activity. Metabolomics and transcriptomics were used to understand the metabolic landscape shifts upon PFAS exposure. We evaluated metabolic changes in benign or tumor cells that lead to epigenomic reprogramming and altered signaling, which ultimately increase tumorigenic risk and tumor aggressiveness. Our studies are the first in the field to provide new and clinically relevant insights regarding novel metabolic and epigenetic states as well as to support the future development of effective preventative and therapeutic strategies for PFAS-induced prostate cancers. Our findings enhance understanding of how PFAS synergize with high-fat diets to contribute to prostate cancer development and establish an important basis to mitigate PFAS exposure.

3 October 2020 in Epigenetics
Verified
Journal Article
Closed access
ZFZeeshan Fazal
Zeeshan Fazal
Ratnakar SinghRatnakar Singh
Ratnakar Singh
FFFang Fang
Fang Fang
EBEmmanuel Bikorimana
Emmanuel Bikorimana
HBHannah Baldwin
Hannah Baldwin
Michael SpinellaMichael Spinella
Michael Spinella
Testicular germ cell tumours (TGCTs) respond well to cisplatin-based therapy. However, cisplatin resistance and poor outcomes do occur. It has been suggested that a shift towards DNA hypermethylation mediates cisplatin resistance in TGCT cells, although there is little direct evidence to support this claim. Here we utilized a series of isogenic cisplatin-resistant cell models and observed a strong association between cisplatin resistance in TGCT cells and a net increase in global CpG and non-CpG DNA methylation spanning regulatory, intergenic, genic and repeat elements. Hypermethylated loci were significantly enriched for repressive DNA segments, CTCF and RAD21 sites and lamina associated domains, suggesting that global nuclear reorganization of chromatin structure occurred in resistant cells. Hypomethylated CpG loci were significantly enriched for EZH2 and SUZ12 binding and H3K27me3 sites. Integrative transcriptome and methylome analyses showed a strong negative correlation between gene promoter and CpG island methylation and gene expression in resistant cells and a weaker positive correlation between gene body methylation and gene expression. A bidirectional shift between gene promoter and gene body DNA methylation occurred within multiple genes that was associated with upregulation of polycomb targets and downregulation of tumour suppressor genes. These data support the hypothesis that global remodelling of DNA methylation is a key factor in mediating cisplatin hypersensitivity and chemoresistance of TGCTs and furthers the rationale for hypomethylation therapy for refractory TGCT patients.

1 November 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
CACostantine Albany
Costantine Albany
ZFZeeshan Fazal
Zeeshan Fazal
Ratnakar SinghRatnakar Singh
Ratnakar Singh
EBEmmanuel Bikorimana
Emmanuel Bikorimana
NANabil Adra
Nabil Adra
Michael SpinellaMichael Spinella
Michael Spinella
Purpose: Germ cell tumors (GCTs) are cured with therapy based on cisplatin, although a clinically significant number of patients are refractory and die of progressive disease. Based on preclinical studies indicating that refractory testicular GCTs are hypersensitive to hypomethylating agents (HMAs), we conducted a phase I trial combining the next‐generation HMA guadecitabine (SGI‐110) with cisplatin in recurrent, cisplatin‐resistant GCT patients.Methods: Patients with metastatic GCTs were treated for five consecutive days with guadecitabine followed by cisplatin on day 8, for a 28‐day cycle for up to six cycles. The primary endpoint was safety and toxicity including dose‐limiting toxicity (DLT) and maximum tolerated dose (MTD).Results: The number of patients enrolled was 14. The majority of patients were heavily pretreated. MTD was determined to be 30 mg/m2 guadecitabine followed by 100 mg/m2 cisplatin. The major DLTs were neutropenia and thrombocytopenia. Three patients had partial responses by RECIST criteria, two of these patients, including one with primary mediastinal disease, completed the study and qualified as complete responses by serum tumor marker criteria with sustained remissions of 5 and 13 months and survival of 16 and 26 months, respectively. The overall response rate was 23%. Three patients also had stable disease indicating a clinical benefit rate of 46%.Conclusions: The combination of guadecitabine and cisplatin was tolerable and demonstrated activity in patients with platinum refractory germ cell cancer.